NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Monday that its Fiscal Year 2013 first-quarter revenues increased 21 percent year over year.

The firm also upped its revenue and profit guidance for the year.

The Salt Lake City-based molecular diagnostics firm reported total revenues of $133.4 million for the three months ended Sept. 30, compared to $110.5 million for the first quarter of FY 2012. It beat analysts' consensus estimate of $129.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.